Risks associated with cognitive function and management strategies in the clinical use of ADT: a systematic review from clinical and preclinical studies-Reference-Cited by-同舟云学术

Risks associated with cognitive function and management strategies in the clinical use of ADT: a systematic review from clinical and preclinical studies

Published:2024-07-31 Issue:8 Volume:32 Page:
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Cui Meng-fan,Chen Li-ming,Jiang Cindy,Ma Bing-zhe,Yuan Fu-wen,Zhao Chen,Liu Shi-min

Funder

Shanghai Municipal Health Commission

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00520-024-08753-3.pdf

Reference86 articles.

1. Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660

2. Chan SY, Ng CF, Lee KW, Yee CH, Chiu PK, Teoh JY, Hou SS et al (2016) Differences in cancer characteristics of Chinese patients with prostate cancer who present with different symptoms. Hong Kong Med J 23(1):6

3. Pishgar F, Ebrahimi H, Saeedi Moghaddam S et al (2018) Global, regional and national burden of prostate cancer, 1990 to 2015: results from the Global Burden of Disease Study 2015. J Urol 199:1224–1232. https://doi.org/10.1016/j.juro.2017.10.044

4. Huggins C, Hodges CV (1972) Studies on Prostatic Cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 22:232–240. https://doi.org/10.3322/canjclin.22.4.232

5. Isbarn H, Boccon-Gibod L, Carroll PR et al (2009) Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol 55:62–75. https://doi.org/10.1016/j.eururo.2008.10.008